Royal Bank of Canada
ESLA icon

Royal Bank of Canada’s Estrella Immunopharma ESLA Stock Holding History

Royal Bank of Canada’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,600
Closed -$7K – 7486
2026
Q1 		$7K Hold
6,600
– – ﹤0.01% 6311
2025
Q4 		$10K Buy
+6,600
New +$12.5K ﹤0.01% 6408

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Royal Bank of Canada's ESLA Position: Q2 2026 in Review

Royal Bank of Canada sold out of Estrella Immunopharma (ESLA) in Q2 2026, closing a stake of 6,600 shares — an estimated $7K sold.

Royal Bank of Canada first reported a position in ESLA in Q4 2025 and held it in 2 quarters. The position peaked at $10K in Q4 2025. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Royal Bank of Canada reported no remaining Estrella Immunopharma position as of Q2 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 6,600 Estrella Immunopharma shares in Q2 2026, an estimated $7K.
  • Royal Bank of Canada first reported a position in Estrella Immunopharma in Q4 2025 and held it in 2 quarters.
  • Royal Bank of Canada's Estrella Immunopharma position peaked at $10K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.